WEST VALLEY CITY, Utah – May 12, 2025 – Nusano, a physics company transforming the production of radioisotopes, today announced its Chief Product Officer, Kevin Haehl, will participate in a radioisotope supply chain panel discussion at the 21st Annual PEGS (Protein & Antibody Engineering) Summit on Wednesday, May 14, 2025, in Boston.
Haehl is a 35-year veteran of the biotech and pharmaceutical manufacturing industries, with extensive experience in operations. During the panel, he will describe existing radiopharmaceutical supply chain constraints and explain how Nusano’s first-of-its-kind radioisotope production platform will deliver high volume, high purity radioisotopes to address existing needs and enable radiopharmaceutical innovation.
WHO:
Nusano Chief Product Officer, Kevin Haehl
WHAT:
Panel Discussion, Isotope Selection, Acquisition, and Production—Challenges and Opportunities
WHEN:
Wednesday, May 14, 2025
11:25 AM Eastern
WHERE:
21st Annual PEGS Summit, Omni Boston Hotel at the Seaport, Boston, MA
# # #
About Nusano
Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. For more, please visit nusano.com.
Contacts:
- Media: Scott Larrivee, Nusano, 608-345-6629, larrivee@nusano.com
- Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, jallaire@lifesciadvisors.com
